Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366770 | 0.80 | HDAC1 (0.65) | HDAC1HDAC2ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL7364106 | 0.72 | KDM4E (0.57) | HDAC1HDAC2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL4495339 | 0.71 | ALDH1A1 (0.56) | ALDH1A1HPGDL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL15029055 | 0.69 | HPGD (0.60) | ALDH1A1HPGDL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL2162221 | 0.68 | CES1 (0.72) | — | |
| SCHEMBL4507350 | 0.67 | SMN1; SMN2 (0.64) | ALDH1A1HPGDL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL30343026 | 0.66 | HPGD (0.64) | ALDH1A1HPGDL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL2706034 | 0.66 | HPGD (0.60) | ALDH1A1HPGDL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL29032386 | 0.66 | HPGD (0.60) | ALDH1A1HPGDL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL29032438 | 0.66 | ALDH1A1 (0.56) | HDAC1ALDH1A1HPGDL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177594-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| WO-2002046129-A2 | INHIBITORS OF HISTONE DEACETYLASE | ABBOTT LABORATORIES (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177594-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC2 4/4885ALDH1A1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.